Date post: | 08-Aug-2015 |
Category: |
Health & Medicine |
Upload: | osuccc-james |
View: | 77 times |
Download: | 0 times |
ASCO Review- 2015 What is new in breast cancer?
Bhuvana Ramaswamy Associate Professor
The Ohio State University
Primary Results of NRG Oncology/NSABP B-35: <br />A Clinical Trial of Anastrozole vs Tamoxifen in <br />Postmenopausal Patients with DCIS
Presented By Richard Margolese at 2015 ASCO Annual Meeting
CALGB 40503 (Alliance)/CTSU 40503/NCT00601900<br /><br />Phase III Trial Evaluating the Addition of Bevacizumab to Letrozole As First-line Endocrine Therapy for Treatment of Hormone-receptor Positive (HR+)<br />Advanced Breast Cancer
Presented By Maura Dickler at 2015 ASCO Annual Meeting
Study Design - CALGB (Alliance) 40503<br />Multicenter Randomized Phase III Trial of 1st-line Letrozole +/- Bev
Presented By Maura Dickler at 2015 ASCO Annual Meeting
Progression-Free Survival<br />CALGB (Alliance) 40503
Presented By Maura Dickler at 2015 ASCO Annual Meeting
Overall Survival<br /> CALGB (Alliance) 40503
Presented By Maura Dickler at 2015 ASCO Annual Meeting
Implications/Future Directions<br />CALGB (Alliance) 40503
Presented By Maura Dickler at 2015 ASCO Annual Meeting
Phase III Trials Endocrine Therapy +/- Bevacizumab (open-label)
Presented By Joseph Sparano at 2015 ASCO Annual Meeting
Abstract LBA502 <br /><br /> A Double Blind Phase 3 Trial of Fulvestrant With or Without Palbociclib in Pre- and Post-menopausal Women With Hormone Receptor-positive, HER2-negative Advanced Breast Cancer That Progressed on Prior Endocrine Therapy<br />(PALOMA3 Study)
Presented By Nicholas Turner at 2015 ASCO Annual Meeting
PALOMA3 Primary Endpoint: PFS<br /> (Investigator-Assessed) ITT Population
Presented By Joseph Sparano at 2015 ASCO Annual Meeting
PALOMA-1: Randomized open-label phase II trial
Presented By Joseph Sparano at 2015 ASCO Annual Meeting
Demographics and Baseline Tumor Characteristics
Presented By Nicholas Turner at 2015 ASCO Annual Meeting
Summary of Key Secondary Efficacy Endpoints
Presented By Nicholas Turner at 2015 ASCO Annual Meeting
Palbociclib in HR+/HER2– BC: Phase III Studies
Presented By Joseph Sparano at 2015 ASCO Annual Meeting
Other CDK Inhibitors in Phase III Trials in Advanced ER-Positive Breast Cancer
Presented By Joseph Sparano at 2015 ASCO Annual Meeting
L Gianni, T Pienkowski, Y-H Im, L-M Tseng, M-C Liu, A Lluch, <br />E Starosławska, J de la Haba-Rodriguez, S-A Im, JL Pedrini, B Poirier, <br />P Morandi, V Semiglazov, V Srimuninnimit, GV Bianchi, <br />V McNally, H Douthwaite, G Ross, P Valagussa
Presented By Luca Gianni at 2015 ASCO Annual Meeting
PFS by tpCR: all treatment arms combined, <br />ITT population
Presented By Luca Gianni at 2015 ASCO Annual Meeting
<br />Oral Abstract Session: <br />Breast Cancer—HER2/ER<br /><br />Substantial efficacy of 12-weeks of neoadjuvant TDM1 with or without endocrine therapy in HER2-positive hormone-receptor-positive early breast cancer: <br />WSG-ADAPT HER2+/HR+ phase II trial<br />
Presented By Nadia Harbeck at 2015 ASCO Annual Meeting
ADAPT HER2+/HR+: <br />Neoadjuvant Phase 2 Trial
Presented By Shanu Modi at 2015 ASCO Annual Meeting
Phase III, randomized study of trastuzumab emtansine ± pertuzumab vs trastuzumab + taxane for first-line treatment of HER2-positive MBC: Primary results from the MARIANNE study
Presented By Paul Ellis at 2015 ASCO Annual Meeting
Objective Response and Duration of Response by IRF
Presented By Paul Ellis at 2015 ASCO Annual Meeting
Neratinib after adjuvant chemotherapy and trastuzumab in HER2-positive early breast cancer: Primary analysis at 2 years of a phase 3 randomized, placebo-controlled trial (ExteNET)
Presented By Arlene Chan at 2015 ASCO Annual Meeting
Is extended therapy with neratinib ready to be a new standard of care?
Presented By Shanu Modi at 2015 ASCO Annual Meeting
Results from a Phase 2 Study of Enzalutamide, an Androgen Receptor Inhibitor, in Advanced AR+ Triple-Negative Breast Cancer (MDV3100-11)
Presented By Tiffany Traina at 2015 ASCO Annual Meeting
Enzalutamide is a Potent Inhibitor of AR Signaling
Presented By Tiffany Traina at 2015 ASCO Annual Meeting
AR Signaling and Triple-Negative Breast Cancer
Presented By Tiffany Traina at 2015 ASCO Annual Meeting
Clinical Benefit in Evaluable and ITT Populations
Presented By Tiffany Traina at 2015 ASCO Annual Meeting
A Multi-Covariate Cox-Proportional Hazards Model of PFS
Presented By Tiffany Traina at 2015 ASCO Annual Meeting
Overall Survival in TNBC Patients on Enzalutamide and According to PREDICT AR Status
Presented By Tiffany Traina at 2015 ASCO Annual Meeting
Prevalence and predictors of androgen receptor (AR) and programmed death-ligand 1 (PD-L1) expression in BRCA1-associated and sporadic triple negative breast cancer (TNBC) (abstr 1005)
Presented By Nadine Tung at 2015 ASCO Annual Meeting